scholarly journals Age of walking and intellectual ability in autism spectrum disorder and other neurodevelopmental disorders: a population‐based study

2020 ◽  
Author(s):  
Alexandra Havdahl ◽  
Cristan Farmer ◽  
Synnve Schjølberg ◽  
Anne‐Siri Øyen ◽  
Pål Surén ◽  
...  
Keyword(s):  
Autism Spectrum Disorder ◽  
Neurodevelopmental Disorders ◽  
Population Based ◽  
Autism Spectrum ◽  
Spectrum Disorder ◽  
Intellectual Ability ◽  
Population Based Study

scholarly journals Psychotropic Medication Prescribing for Neuropsychiatric Comorbidities in Individuals Diagnosed with Autism Spectrum Disorder (ASD) in the UK

2019 ◽  
Vol 50 (2) ◽  
pp. 625-633 ◽  
Author(s):  
Basmah H. Alfageh ◽  
Kenneth K. C. Man ◽  
Frank M. C. Besag ◽  
Tariq M. Alhawassi ◽  
Ian C. K. Wong ◽  
...  
Keyword(s):  
Autism Spectrum Disorder ◽  
Psychotropic Medication ◽  
Population Based ◽  
Autism Spectrum ◽  
Spectrum Disorder ◽  
Population Based Study ◽  
Changing Trend ◽  
Neuropsychiatric Comorbidities ◽  
Medication Prescribing ◽  
The Uk

Abstract Autism spectrum disorder (ASD) is a lifelong disorder. In the UK, risperidone is the only psychotropic medication approved for the management of the behavioural symptoms that may accompany autism. This is a population-based study aimed to provide an evaluation of the changing trend in the incidence and prevalence of ASD and to analyse the pattern of psychotropic medication prescribing in the UK. 20,194 patients with ASD were identified. The prevalence increased 3.3-fold from 0.109 per 100 persons in 2009 to 0.355 per 100 persons in 2016. Approximately one-third of the identified cohort was prescribed at least one psychotropic medication. Although the medications approved to manage the symptoms of ASD are limited, the prescribing of such medications is increasing.

Association between preeclampsia and autism spectrum disorder: a population‐based study

2019 ◽  
Vol 61 (2) ◽  
pp. 131-139 ◽  
Author(s):  
Gillian M. Maher ◽  
Gerard W. O'Keeffe ◽  
Christina Dalman ◽  
Patricia M. Kearney ◽  
Fergus P. McCarthy ◽  
...  
Keyword(s):  
Autism Spectrum Disorder ◽  
Population Based ◽  
Autism Spectrum ◽  
Spectrum Disorder ◽  
Population Based Study

scholarly journals In-Utero SSRI and SNRI Exposure and the Risk of Neurodevelopmental Disorders in Children: A Population-Based Retrospective Cohort Study Utilizing Linked Administrative Data

2018 ◽  
Vol 3 (4) ◽  
Author(s):  
Deepa Singal ◽  
Dan Chateau ◽  
Matthew Dahl ◽  
Shelley Derksen ◽  
Chelsea Ruth ◽  
...  
Keyword(s):  
Autism Spectrum Disorder ◽  
Anxiety Disorder ◽  
Disease Severity ◽  
Administrative Data ◽  
Neurodevelopmental Disorders ◽  
Population Based ◽  
In Utero ◽  
Autism Spectrum ◽  
Hazard Ratio ◽  
Spectrum Disorder

IntroductionMany studies demonstrating an association between in utero exposure to serotonergic antidepressants and higher risk of neurodevelopmental disorders in children are confounded by history of maternal depression and disease severity. We conducted a population-based analysis of women diagnosed with mood/anxiety disorder, a patient population for whom pharmacotherapy is clearly indicated. Objectives and ApproachUsing linked population-based administrative data, we identified all mother-newborn pairs in Manitoba (born 1996 to 2009, with follow-up through 2014). High dimensional propensity scores and inverse probability treatment weighting were used to address confounding by indication and disease severity. The final trimmed cohort consisted of mothers who were diagnosed with a mood/anxiety disorder from 90 days prior to conception until delivery (n=4995). Cox Proportional Hazard Regression models were used to estimate risk of Autism Spectrum Disorder, epilepsy and attention deficit hyperactivity disorder (ADHD) in offspring. In addition to clinical data, we used novel education data to define outcomes in children. ResultsAmong the cohort of mothers diagnosed with a mood/anxiety disorder during pregnancy or up to 90 days before, 16.8% received at least two dispensations of an SSRI or SNRI during pregnancy. We did not observe an association between use of SSRIs/SNRIs during pregnancy and increased risk of Autism Spectrum Disorder (hazard ratio 0.92; 95% CI 0.42 to 2.03), epilepsy (hazard ratio 1.21; 95% CI 0.48 to 3.05), or ADHD (hazard ratio 1.13, 95% CI 0.78 to 1.64) among offspring. Conclusion/ImplicationsIn the absence of randomized control trials, large observation studies using sophisticated data analysis are the gold standard of evidence to help patients and clinicians making the decision to continue antidepressant use during pregnancy. Results of this study reassure women for whom the medication is clinically indicated.

scholarly journals Disparities in adversity among children with autism spectrum disorder: a population-based study

2016 ◽  
Vol 58 (11) ◽  
pp. 1124-1131 ◽  
Author(s):  
Kristin L Berg ◽  
Cheng-Shi Shiu ◽  
Kruti Acharya ◽  
Bradley C Stolbach ◽  
Michael E Msall
Keyword(s):  
Autism Spectrum Disorder ◽  
Children With Autism ◽  
Population Based ◽  
Autism Spectrum ◽  
Spectrum Disorder ◽  
Population Based Study
Sign in / Sign up

Export Citation Format

Share Document